NIAID Email Alert: Tuberculosis Vaccine Design R01, South Africa Program

Funding Opportunities

• PAR-16-253, Mechanisms of Mycobacterial-Induced Immunity in HIV-Infected and Uninfected Individuals to Inform Innovative Tuberculosis Vaccine Design (R01)
• RFA-AI-16-039, Revision Applications for U.S.-South Africa Program for Collaborative Biomedical Research (R01)
• RFA-AI-16-040, Revision Applications for U.S.-South Africa Program for Collaborative Biomedical Research (U01)

For more opportunities, see the NIAID Funding Opportunities List. 

You can follow us on Twitter: @NIAIDFunding.